BFM
IBRX icon

Boothbay Fund Management’s ImmunityBio IBRX Stock Holding History

Boothbay Fund Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-14,458
Closed -$55K – 944
2019
Q4 		$55K Buy
+14,458
New +$24.6K ﹤0.01% 801

Other funds holding IBRX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Boothbay Fund Management's IBRX Position: Q1 2020 in Review

Boothbay Fund Management sold out of ImmunityBio (IBRX) in Q1 2020, closing a stake of 14,458 shares — an estimated $55K sold.

Boothbay Fund Management first reported a position in IBRX in Q4 2019 and held it in 1 quarter. The position peaked at $55K in Q4 2019. 49 funds tracked by Wall St. Rank hold IBRX as of Q1 2020.

  • Boothbay Fund Management reported no remaining ImmunityBio position as of Q1 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 14,458 ImmunityBio shares in Q1 2020, an estimated $55K.
  • Boothbay Fund Management first reported a position in ImmunityBio in Q4 2019 and held it in 1 quarter.
  • Boothbay Fund Management's ImmunityBio position peaked at $55K in Q4 2019.
  • 49 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2020.

Based on Boothbay Fund Management's 13F filing for Q1 2020, filed 15 May 2020.